## **Prior Authorization Form**

(\*Required)



**Note:** Please provide as much information as possible on this form. Missing data may cause processing delays for requested authorization(s). Attach additional sheets to this form if necessary.

Please fax the completed PA form and any additional informational sheets to Nirvanahealth at the following fax number: +1(866) 871-8565

Patient Information	Prescriber Information
Patient Name:	Prescriber Name:
Health Plan Name:	Prescriber Address:
Patient Insurance Id:	
Patient Date of Birth:	Prescriber Phone: ( )
Patient Phone:	Prescriber Fax: ( )
	Prescriber Specialty:
	Prescriber DEA:
	Prescriber NPI:
Medica	tion & Medical Information
Requested Drug(s) & Strength(s):	[ ] Tukysa 150 mg tablet [ ] Tukysa 50 mg tablet
Requested Daily Quantity Limit – Amount:	
Requested Daily Quantity Limit – Days:	
Requested Quantity Limit Over Time – Amount:	
Requested Quantity Limit Over Time – Days:	
Requested Quantity Per Rx – Amount:	
Expected Length of Therapy:	
Directions:	
Diagnosis and Diagnosis Codes (ICD-10 Standard Codes):	
List drugs used previously to treat the same condition:	
Additional clinical information or history. Please include any relevant test results and/or medical record notes:	
	Overtionnains
	Questionnaire  the provider, certify and attest that the information provided is complete by information to RxAdvance that RxAdvance determines is reasonably tapply)
[] Yes	•••
[] No	
Q2: Is the member currently treated with this medical	ion? (Chack only one that apply)
[] Yes (please list start date of therapy (month/d	

## **Prior Authorization Form**



[ ] No	
Q3: What is the member's diagnosis? (Check only one that apply)	
[ ] Advanced unresectable breast cancer	
[ ] Metastatic breast cancer	
[ ] Other (please specify the member's diagnosis and provide clinical rationale for the request)(*Required)	
Q4: What is the member's diagnosis? (Check only one that apply)	
[ ] Advanced unresectable breast cancer	
[ ] Metastatic breast cancer	
[ ] Other (please specify the member's diagnosis and provide clinical rationale for the request)(*Required)	
Q5: Is the disease positive for human epidermal growth factor receptor 2 (HER2)? (Check only one that apply)	)
[ ] Yes (please provide supporting documents)	(*Required)
[ ] No (please specify clinical rationale for the request)(*Required)	
Q6: Will the requested drug be used in combination with trastuzumab and capecitabine? (Check only one that	t apply)
[ ] Yes (please specify the drug name)(*	Required)
[ ] No (please provide clinical rationale for the request)(*Required)	
Q7: Has the member received received one or more prior anti-HER2 based regimens (e.g., trastuzumab, perturastuzumab emtansine)? (Check only one that apply)	uzumab, ado-
[ ] Yes (please specify the drug name and the start and end date(s) of therapy (month/year))(*Required)	
[ ] No (please provide clinical rationale for the request)(*Required)	
Q8: Is the requisted medication prescribed by or in consultation with an oncologist? (Check only one that app	ply)
[] Yes	
[ ] No (please provide clinical rationale for the request)(*Required)	
<u>Attestation:</u> I attest the information provided is true and accurate to the best of my knowledge. I understand that the He Medical Group or its designated representatives may perform a routine audit and request the medical information necess accuracy of the information reported on this form.	
Signature of Prescriber or Authorized Representative:  Date:	
Print Authorized Representative Name:	